Abstract
Herpes simplex viruses (HSVs) have entered clinical trials as oncolytic agents. The following properties make them good candidates. It is a mild pathogen; drugs (Aciclovir) are available to control viral infection; the large genome is amenable to genetic engineering, they can be rendered cancer-specific by deletion of genes, envelope glycoproteins allow the insertion of heterologous ligands to achieve modification of the natural tropism. Genetically modified HSVs have been thoroughly tested in humans. New generation recombinants retargeted to cancer-specific heterologous receptors have been generated and are presently evaluated in pre-clinical settings. They will be reviewed along with the molecular bases of cancer specificity and the strategies for the enhancement of oncolytic potential of HSV recombinants.
Keywords: Herpes simplex virus, oncolytic virus, oncolytic virotherapy, glioma, γ1 34.5, HER-2, mild pathogen, natural tropism, cancer specificity, HSV recombinants
Current Pharmaceutical Biotechnology
Title:The Molecular Basis of Herpesviruses as Oncolytic Agents
Volume: 13 Issue: 9
Author(s): Laura Menotti, Gabriella Campadelli-Fiume, Patrizia Nanni, Pier Luigi Lollini and Carla De Giovanni
Affiliation:
Keywords: Herpes simplex virus, oncolytic virus, oncolytic virotherapy, glioma, γ1 34.5, HER-2, mild pathogen, natural tropism, cancer specificity, HSV recombinants
Abstract: Herpes simplex viruses (HSVs) have entered clinical trials as oncolytic agents. The following properties make them good candidates. It is a mild pathogen; drugs (Aciclovir) are available to control viral infection; the large genome is amenable to genetic engineering, they can be rendered cancer-specific by deletion of genes, envelope glycoproteins allow the insertion of heterologous ligands to achieve modification of the natural tropism. Genetically modified HSVs have been thoroughly tested in humans. New generation recombinants retargeted to cancer-specific heterologous receptors have been generated and are presently evaluated in pre-clinical settings. They will be reviewed along with the molecular bases of cancer specificity and the strategies for the enhancement of oncolytic potential of HSV recombinants.
Export Options
About this article
Cite this article as:
Menotti Laura, Campadelli-Fiume Gabriella, Nanni Patrizia, Luigi Lollini Pier and De Giovanni Carla, The Molecular Basis of Herpesviruses as Oncolytic Agents, Current Pharmaceutical Biotechnology 2012; 13 (9) . https://dx.doi.org/10.2174/138920112800958931
DOI https://dx.doi.org/10.2174/138920112800958931 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
On the Epistemological Crisis in Genomics
Current Genomics Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology Patent Selections:
Current Biomarkers (Discontinued) CYP4 Enzymes As Potential Drug Targets: Focus on Enzyme Multiplicity, Inducers and Inhibitors, and Therapeutic Modulation of 20- Hydroxyeicosatetraenoic Acid (20-HETE) Synthase and Fatty Acid ω- Hydroxylase Activities
Current Topics in Medicinal Chemistry Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Current Medicinal Chemistry 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry miR-15b and miR-21 as Circulating Biomarkers for Diagnosis of Glioma
Current Genomics Natural Monophenols as Therapeutics, Antioxidants and Toxins; Electron Transfer, Radicals and Oxidative Stress
The Natural Products Journal Role of the Cannabinoid System in Pain Control and Therapeutic Implications for the Management of Acute and Chronic Pain Episodes
Current Neuropharmacology The Synergistic Cytotoxic and Apoptotic Effect of Resveratrol and Naringenin on Y79 Retinoblastoma Cell Line
Anti-Cancer Agents in Medicinal Chemistry The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism Novel Oncogenic Protein Kinase Inhibitors for Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents ADP-Ribosyl Cyclase as a Therapeutic Target for Central Nervous System Diseases
Central Nervous System Agents in Medicinal Chemistry The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Medicinal Chemistry Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs
Current Medicinal Chemistry Turning Tumor-Promoting Copper into an Anti-Cancer Weapon via High-Throughput Chemistry
Current Medicinal Chemistry Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Anti-Cancer/Anti-Tumor
Current Bioactive Compounds CD44 and EpCAM: Cancer-Initiating Cell Markers
Current Molecular Medicine New Framework for the Discovery of PRC2 Inhibitors: Epigenetic Drugs
Current Drug Targets